Ramon Garcia-Septien, MD
Sports Medicine · Hialeah, FLNPI 1073566170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Novo Nordisk at 32.2% of the total. Reporting peaked in 2021 at $719 and has fallen 89.8% since, to $73 in 2025. That places this record below the midpoint for sports medicine clinicians in FL, where the typical reported total is $1,516.
Across 88 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$596
- Lilly USA, LLC$394
- Boehringer Ingelheim$148
- AstraZeneca$135
- AbbVie$107
- Idorsia Pharmaceuticals US Inc$101
- plus $370 from 9 others
Across 21 payments — averaging $5914.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$124K
What the payments were for
- Food & beverage$1,851100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $596 |
| Lilly USA, LLC | 26 | $394 |
| Boehringer Ingelheim | 7 | $148 |
| AstraZeneca | 3 | $135 |
| AbbVie(2 entities) | 6 | $107 |
| Idorsia Pharmaceuticals US Inc | 2 | $101 |
| Astellas Pharma US Inc | 5 | $90 |
| GSK | 4 | $81 |
| Amarin Pharma, Inc. | 2 | $51 |
| Merck | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Intra-sana Laboratories | 1 | $23 |
| Pfizer | 1 | $21 |
| IBSA Pharma Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$117
How this compares
$1,851 in reported general payments places this provider in the 50th percentile of 402 sports medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $102,395 |
| TrulicityDulaglutide | 42 | $42,059 |
| EliquisApixaban | 28 | $34,888 |
| FarxigaDapagliflozin Propanediol | 31 | $34,746 |
| LinzessLinaclotide | 43 | $28,211 |
| EntrestoSacubitril/Valsartan | 21 | $24,054 |
| JanuviaSitagliptin Phosphate | 14 | $22,057 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,654 |
| MounjaroTirzepatide | 17 | $18,045 |
| Risedronate Sodium | 137 | $17,890 |
| Memantine Hcl ErMemantine Hcl | 128 | $16,257 |
| XareltoRivaroxaban | 18 | $14,772 |
| Piroxicam | 114 | $12,556 |
| Omega-3 Acid Ethyl Esters | 118 | $10,632 |
| TradjentaLinagliptin | 11 | $9,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $596 | $102,39591 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $394 | $60,10459 claims |
| AstraZenecaFarxiga, Symbicort | $135 | $38,97948 claims |
| PfizerEliquis | $21 | $34,88828 claims |
| AbbVieLinzess, Synthroid | $107 | $29,53755 claims |
| MerckJanuvia | $34 | $22,05714 claims |
| GSKTrelegy Ellipta | $81 | $19,65420 claims |
| Boehringer IngelheimTradjenta | $148 | $9,41611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 402 sports medicine providers in Florida.
Other sports medicine in Hialeah
- Jose PerezHialeah$38K
- Kevin WangHialeah$31K
- Lee KaplanMiami$11.3M
- Patrick SmithNaples$2.9M
- Ryan SimovitchWest Palm Beach$1.1M
- Bruce LevyOrlando$816K
- Gautam YagnikMiami$440K
- Carl DilellaVero Beach$384K
- Adam AnzGulf Breeze$354K
- Stanton LongeneckerJacksonville$330K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.